CMS reopens coverage determination on next-gen sequencing for cancer patients

CMS Monday reopened its national coverage determination (NCD) for next generation sequencing (NGS).
The move follows pressure from healthcare organizations that argued the agency's original decision on NGS would prevent Medicare beneficiaries with early-stage cancer from accessing the tests.